The Pentagon began requiring testosterone blood tests for male service members age 30 and older on Wednesday, releasing clinical guidance that took effect immediately and covers the active-duty and reserve forces.
The Defense Health Agency released a set of clinical guidelines that fold the screening into service members' regular periodic health assessments. Men age 30 and older will receive mandatory testosterone blood tests, while younger men will be tested only on request or if clinicians identify warning signs. Service members diagnosed with hypogonadism, the clinical term for low testosterone, will receive follow-up screening and treatment options including testosterone replacement therapy.
The guidance implements a directive Defense Secretary Pete Hegseth announced over the summer and framed as a readiness measure. The department has emphasized that while the initial screening is compulsory for eligible members, subsequent treatment is voluntary. Hegseth said in July that if treatment is recommended, "it's entirely your choice to receive testosterone replacement therapy."
A Screening Program Ahead of the Evidence Review
The timing is what makes this more than a military personnel story. The Food and Drug Administration plans to convene a meeting of experts to discuss the medical use of testosterone in mid-September, roughly two weeks after the screening program takes effect.
In other words, a mandatory population-wide screening program is being implemented before the federal regulator holds its scheduled discussion of the underlying clinical questions. That sequence is unusual for a screening policy and is the specific point drawing physician criticism.
Doctors have raised concerns, according to reporting on the guidance that took effect immediately, that broad testosterone testing could lead to unnecessary or potentially harmful treatment. They say there is little evidence that universal screening for low testosterone among military personnel would improve combat readiness.
The concern has a recognizable clinical shape. Testosterone levels vary substantially by time of day, by recent illness, by sleep, and by acute stress, all of which are common in military life. Screening people without symptoms produces borderline results, borderline results generate repeat testing and specialist referrals, and some proportion of those encounters end in a prescription for a person who had no symptoms to begin with.
Testosterone replacement is not a benign intervention. It can suppress sperm production and affect fertility, raise red blood cell counts, and requires ongoing monitoring. For a force with a large population of service members in their thirties who may want children, fertility effects are a concrete consideration rather than a theoretical one.
There is a countervailing argument, and it deserves a fair hearing. At a prior FDA expert panel on testosterone, an Army urologist said the high operational tempo and stress service members experience can lower testosterone, sometimes acutely and sometimes over the longer term. The new guidance calls testosterone a critical biological marker for readiness and warns that service members may be particularly at risk of decreased levels.
What the Guidance Covers for Women
The policy is not limited to men, though it works differently. For women, the guidance does not mandate routine testosterone blood tests. It calls for screening for fatigue and disrupted menstrual cycles that can be associated with hormonal dysregulation and conditions described as low energy availability and relative energy deficiency in sport.
The distinction matters because the two halves of the policy rest on different footing. Mandatory blood testing of men without symptoms is the contested part. Asking a clinician to notice fatigue and menstrual disruption in a heavily trained population is closer to standard practice.
That framing points toward a genuine and underrecognized problem. Low energy availability, in which intake does not match the demands of heavy physical training, is well documented in athletes and affects menstrual function, bone density, and injury risk. Screening for it is not the same proposition as screening for low testosterone in men without symptoms, and the evidence base is different.
The document also lays out when it is appropriate to prescribe off-label testosterone in women, specifically for postmenopausal women with unusually low sexual desire. That is an area where prescribing standards remain contested among endocrinologists.
The Civilian Read-Across
About two million people serve in the active and reserve components, which makes this one of the largest hormone screening programs ever implemented in the United States. Its effects will not stay inside the military. The full text sits in the Defense Health Agency policy memorandum, and the department framed the goal in its announcement of the policy as investing in the health of service members and maximizing force readiness.
The civilian market for testosterone therapy has expanded rapidly through direct-to-consumer telehealth clinics, many of which advertise on the same symptoms the military guidance describes: fatigue, low energy, reduced motivation. A large federal program that treats routine testosterone screening as standard practice gives those marketing claims an implicit endorsement, whether or not that is intended.
For civilian readers, the useful distinction is between testing driven by symptoms and testing driven by curiosity. Established endocrine guidelines recommend measuring testosterone in men who have consistent symptoms and signs of deficiency, using an early-morning sample confirmed by a second test, not as a routine screen. Anyone considering a low-testosterone clinic should ask whether the clinic confirms an abnormal result with a repeat morning test, whether it evaluates other causes of fatigue such as sleep apnea, thyroid disease, depression or anemia, and what monitoring it provides after starting therapy. Cost is worth asking about too, since insurers frequently decline to cover testosterone therapy prescribed without a documented deficiency.
Nobody should start or stop testosterone therapy based on a single result or an advertisement. That is a conversation with a physician who can look at the whole clinical picture.
Several things remain unresolved. The Defense Health Agency has not specified a timeline for full implementation across branches or for the first required testing cycle to be completed. The department has not published cost estimates. The FDA panel in mid-September has not met, and its conclusions are unknown.
The underlying empirical question also remains open: whether screening an entire force produces measurable readiness gains, or primarily produces treatment costs, side effects, and a large volume of clinical encounters for people who were not symptomatic. Service members with questions should raise them at their next periodic health assessment, where the screening will now be part of the visit.
Key Questions Answered
Who has to be tested? Active-duty and reserve male service members age 30 and older receive mandatory testosterone blood tests during regular periodic health assessments.
What about service members under 30? They are tested only on request or if a clinician identifies warning signs, with optional annual screening offered.
Are women included? Women are not subject to mandatory testosterone blood tests. Providers are directed to screen for fatigue and menstrual irregularities linked to low energy availability.
Is treatment mandatory? No. The department says screening is compulsory, but any subsequent treatment, including testosterone replacement therapy, is the service member's choice.
Why are doctors questioning it? Physicians say there is little evidence that universal screening improves readiness, and that testing people without symptoms can lead to unnecessary treatment.
What is the FDA doing? The agency plans an expert meeting in mid-September on the medical use of testosterone, after the military program has already taken effect.
Should civilians get tested? Endocrine guidelines recommend testing men with consistent symptoms of deficiency using confirmed early-morning samples, not routine screening. Discuss it with a physician rather than a marketing website.
